Skip to main content

Advertisement

Log in

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

In some reports, 5-fluorouracil has been associated with modest activity in patients with neuroendocrine tumors. Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors.

Methods

Patients with metastatic neuroendocrine tumors (excluding small-cell carcinoma) were treated with pemetrexed administered intravenously at a dose of 500 mg/m2 every 21 days. To reduce potential toxicity, patients also received folic acid, vitamin B12 supplementation, and peri-infusional treatment with dexamethasone. Patients were followed for response, toxicity, and survival.

Results

The study was designed with a total accrual goal of 32 patients. Due to lack of radiographic responses in patients during the study period, accrual was terminated at 17. However, one patient achieved a delayed partial response following discontinuation of pemetrexed. Ten patients were evaluable for biochemical response; five (50%) experienced >50% decrease in plasma chromogranin A. Among the 17 patients, 5 (29%) discontinued therapy due to treatment-related toxicity. The median overall survival was 12.1 months.

Conclusion

Pemetrexed does not appear to have significant antitumor activity in patients with advanced neuroendocrine tumors. The limited antitumor activity and potential toxicity associated with pemetrexed mirrors experience with the majority of other cytotoxic agents in patients with neuroendocrine tumors. Investigation of novel, molecularly targeted agents may offer more promise in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Moertel CG (1983) Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1(11):727–740

    CAS  PubMed  Google Scholar 

  2. Engstrom P, Lavin P, Moertel C, Folsch E, Douglass H (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2:1255–1259

    CAS  PubMed  Google Scholar 

  3. Kouvaraki M, Ajani J, Hoff P, Wolff R, Evans D, Lozano R, Yao J (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771

    Article  CAS  PubMed  Google Scholar 

  4. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23(22):4897–4904

    Article  CAS  PubMed  Google Scholar 

  5. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM (2002) Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 57(2):169–183

    Article  CAS  Google Scholar 

  6. Strosberg J, Choi J, Gardner N, Kvols L (2008) First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide. J Clin Oncol 26(May 20 Suppl):Abstract 4612 (2009 ASCO Annual Meeting Proceedings)

  7. Kulke M, Stuart K, Earle C, Bhargava P, Clark J, Enzinger P, Meyerhardt J, Attawia M, Lawrence C, Fuchs C (2006) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24(18S, June 20 Suppl):Abstract 4044 (2006 ASCO Annual Meeting Proceedings Part I)

  8. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406

    Article  CAS  PubMed  Google Scholar 

  9. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA (1999) Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26(2 Suppl 6):42–47

    CAS  PubMed  Google Scholar 

  10. Schultz RM, Patel VF, Worzalla JF, Shih C (1999) Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 19(1A):437–443

    CAS  PubMed  Google Scholar 

  11. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57(6):1116–1123

    CAS  PubMed  Google Scholar 

  12. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4):363–373

    Article  CAS  PubMed  Google Scholar 

  13. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar C, Manegold S, Paul P, Paoletti L, Einhorn PA, Bunn Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597

    Article  CAS  PubMed  Google Scholar 

  14. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644

    Article  CAS  PubMed  Google Scholar 

  15. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21(8):1556–1561

    Article  CAS  PubMed  Google Scholar 

  16. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  17. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4):1059–1064

    Article  CAS  PubMed  Google Scholar 

  18. Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC (2009) Pemetrexed-induced pneumonitis: a case report. Clin Lung Cancer 10(5):364–366

    Article  PubMed  Google Scholar 

  19. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J (2001) A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91(8):1543–1548

    Article  CAS  PubMed  Google Scholar 

  20. Kulke M, Fuchs C, Stuart K, Ryan D, Enzinger P, Vincitore M, Berg D, Clark J, Mayer R (2004) Phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Investig 22(3):353–359

    Article  CAS  Google Scholar 

  21. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS (2004) A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101(5):934–939

    Article  CAS  PubMed  Google Scholar 

  22. Terris B, Scoazec J, Rubbia L (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 32:133–138

    Article  CAS  PubMed  Google Scholar 

  23. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316–1323

    Article  CAS  PubMed  Google Scholar 

  24. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403–3410

    Article  CAS  PubMed  Google Scholar 

  25. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 25(18S, June 20 Suppl):Abstract 4504 (2007 ASCO Annual Meeting Proceedings Part I)

  26. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148–1154

    Article  CAS  PubMed  Google Scholar 

  27. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26(26):4311–4318

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Support for this study was provided by the Stephen and Caroline Kaufer Fund for Neuroendocrine Tumor Research. Pemetrexed was supplied by Lilly, Inc. The authors acknowledge additional support from the Saul and Gitta Kurlat Fund for Neuroendocrine Tumor Research, and NCI grants CA093401 (MHK) and P50 CA127003 (DF/HCC SPORE in Gastrointestinal Cancer).

Conflict of interest statement

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer A. Chan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chan, J.A., Zhu, A.X., Stuart, K. et al. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol 66, 961–968 (2010). https://doi.org/10.1007/s00280-010-1248-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1248-6

Keywords

Navigation